IL6 and autoimmune disease: As evidence of the proinflammatory effects, a report revealed that IL6 treatment reduced the survival of liver cancer cells [13] and tocilizumab, an IL6 blocker, has been used as a therapeutic drug for autoimmune diseases in rheumatology.